Publications
Detailed Information
Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yuk, Hyeong Dong | - |
dc.contributor.author | Jeong, Chang Wook | - |
dc.contributor.author | Kwak, Cheol | - |
dc.contributor.author | Kim, Hyeon Hoe | - |
dc.contributor.author | Moon, Kyung Chul | - |
dc.contributor.author | Ku, Ja Hyeon | - |
dc.date.accessioned | 2019-11-07T04:53:50Z | - |
dc.date.available | 2019-11-07T13:54:37Z | - |
dc.date.issued | 2019-09-09 | - |
dc.identifier.citation | BMC Cancer, 19(1):897 | ko_KR |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.uri | https://hdl.handle.net/10371/162641 | - |
dc.description.abstract | Background
We evaluated the clinical efficacy and prognosis of muscle-invasive bladder cancer according to the basal/squamous-like (BASQ) classification system based on immunohistochemical staining [CK5/6(+), CK14(+), GATA3(−), and FOXA1(−)]. Methods One hundred patients diagnosed with muscle-invasive bladder cancer (cT2-4 N0-3 M0) were included in the study. All patients underwent radical cystectomy after transurethral removal of bladder tumor. Immunostaining was performed for CK5/6, CK14, FOXA1, and GATA3 antibodies on tissue microarray slides, and expression patterns were quantitatively analyzed using a scanning program. Results The median follow-up time was 77.4 (interquartile range: 39–120.9) months. The mean age of the patients was 65.1 ± 11.2 years. FOXA1 or CK14 expression greater than 1% was respectively positively and negatively correlated with overall survival (OS; p = 0.011 and p = 0.042, respectively), cancer-specific survival (CSS; p = 0.050 for both), and recurrence-free survival (RFS; p = 0.018 and p = 0.040, respectively). For CK5/6+ and GATA3- or FOXA1- expression, 10% CK5/6+ cells were negatively correlated with OS (p = 0.032 and p = 0.039, respectively) and with RFS in combination with FOXA1- only (p = 0.050). Conclusions In this study, CK14 expression was associated with a poor prognosis. The new classification system of bladder cancer based on molecular characteristics is expected to helpful tool for the establishment of personalized treatment strategies and associated prediction of therapeutic responses. | ko_KR |
dc.description.sponsorship | This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (Grant number: 2016R1A2B4011623). No funders had any role in study concept and design, experiments, analysis of data, writing manuscript, or the decision for publication.
This study was supported by the 2015 Korean Urologic Oncology Society Grant | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BioMed Central | ko_KR |
dc.subject | Basal cell | ko_KR |
dc.subject | Immunohistochemistry | ko_KR |
dc.subject | Molecular subtype | ko_KR |
dc.subject | Neoplasm metastasis | ko_KR |
dc.subject | Squamous cell | ko_KR |
dc.subject | Urinary bladder neoplasms | ko_KR |
dc.title | Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 육형동 | - |
dc.contributor.AlternativeAuthor | 정창욱 | - |
dc.contributor.AlternativeAuthor | 곽철 | - |
dc.contributor.AlternativeAuthor | 김현회 | - |
dc.contributor.AlternativeAuthor | 문경철 | - |
dc.contributor.AlternativeAuthor | 구자현 | - |
dc.identifier.doi | 10.1186/s12885-019-6042-1 | - |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s). | - |
dc.date.updated | 2019-09-15T03:33:04Z | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.